Liver fat accumulation is associated with circulating PCSK9

Annals of Medicine

Volumn 48, Issue 5, 2016, Pages 384-391

  Ruscica, Massimiliano ^a   Ferri, Nicola ^b   Macchi, Chiara ^a   Meroni, Marica ^a   Lanti, Claudia ^c   Ricci, Chiara ^a   Maggioni, Marco ^c   Fracanzani, Anna Ludovica ^a,c   Badiali, Sara ^c   Fargion, Silvia ^a,c   Magni, Paolo ^a   Valenti, Luca ^a,c   Dongiovanni, Paola ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Lipids; lipoproteins metabolism; lipoproteins receptors; liver; NAFLD

Indexed keywords

ALANINE AMINOTRANSFERASE; FAT; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; FAS ANTIGEN; FAS PROTEIN, HUMAN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT CONTENT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX; STAGING; BLOOD; GENETICS; LIPOGENESIS; LIVER; METABOLISM; MIDDLE AGED; PROGNOSIS; RISK FACTOR;

ADULT; ANTIGENS, CD95; APOLIPOPROTEIN B-100; FEMALE; HUMANS; LIPOGENESIS; LIPOPROTEINS, LDL; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; PROPROTEIN CONVERTASE 9; RISK FACTORS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84969785189     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890.2016.1188328     Document Type: Article

References (32)

1. G.Marchesini, M.Brizi, A.M.Morselli-Labate, G.Bianchi, E.Bugianesi, A.J.McCullough,. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–5.
2. R.Rametta, E.Mozzi, P.Dongiovanni, B.M.Motta, M.Milano, G.Roviaro,. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. Int J Obes (2005). 2013;37:986–92.
3. E.Bugianesi, A.Gastaldelli, E.Vanni, R.Gambino, M.Cassader, S.Baldi,. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease:sites and mechanisms. Diabetologia. 2005;48:634–42.
4. G.Musso, R.Gambino, M.Cassader Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013;52:175–91.
5. P.Dongiovanni, S.Petta, C.Maglio, A.L.Fracanzani, R.Pipitone, E.Mozzi,. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61:506–14.
6. M.Blachier, H.Leleu, M.Peck-Radosavljevic, D.C.Valla, F.Roudot-Thoraval The burden of liver disease in Europe:a review of available epidemiological data. J Hepatol. 2013;58:593–608.
7. G.Targher, C.P.Day, E.Bonora Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50.
8. N.Ferri, A.Corsini, C.Macchi, P.Magni, M.Ruscica Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism:experimental animal models and clinical evidence. Transl Res. 2015. doi:10.1016/j.trsl.2015.10.004.
9. N.G.Seidah, S.Benjannet, L.Wickham, J.Marcinkiewicz, S.B.Jasmin, S.Stifani,. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100:928–33.
10. N.G.Seidah, A.Prat The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367–83.
11. J.K.Alder, J.J.Chen, L.Lancaster, S.Danoff, S.C.Su, J.D.Cogan,. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. 2008;105:13051–6.
12. Y.L.Guo, W.Zhang, J.J.Li PCSK9 and lipid lowering drugs. Clin Chim Acta. 2014;437:66–71.
13. J.Cohen, A.Pertsemlidis, I.K.Kotowski, R.Graham, C.K.Garcia, H.H.Hobbs Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161–5.
14. G.Tibolla, G.D.Norata, R.Artali, F.Meneghetti, A.L.Catapano Proprotein convertase subtilisin/kexin type 9 (PCSK9):from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis. 2011;21:835–43.
15. B.Cariou, B.Charbonnel, B.Staels. Thiazolidinediones and PPARγ agonists:time for a reassessment. Trends Endocrinol Metab. 2012;23:205–15.
16. M.Ruscica, C.Ricci, C.Macchi, P.Magni, R.Cristofani, J.Liu,. Suppressor of Cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem. 2016;291:3508–19.
17. B.Cariou, C.Langhi, M.Le Bras, M.Bortolotti, K.A.Le, F.Theytaz,. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab (Lond). 2013;10:4.
18. S.G.Lakoski, T.A.Lagace, J.C.Cohen, J.D.Horton, H.H.Hobbs Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94:2537–43.
19. H.Tavori, I.Giunzioni, I.M.Predazzi, D.Plubell, J.Miles, R.M.DeVay,. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE - and LDLR-mediated mechanisms. Cardiovasc Res. 2016;110:268–78.
20. P.Dongiovanni, S.Petta, V.Mannisto, R.Margherita Mancina, R.Pipitone, V.Karja,. Statin use and nonalcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–12.
21. P.Dongiovanni, B.Donati, R.Fares, R.Lombardi, R.M.Mancina, S.Romeo,. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013;19:6969–78.
22. D.E.Kleiner, E.M.Brunt, M.Van Natta, C.Behling, M.J.Contos, O.W.Cummings,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
23. G.Musso, R.Gambino, M.Cassader, G.Pagano A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104.
24. P.Costet, B.Cariou, G.Lambert, F.Lalanne, B.Lardeux, A.L.Jarnoux,. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem. 2006;281:6211–18.
25. C.Werner, M.M.Hoffmann, K.Winkler, M.Bohm, U.Laufs Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol. 2014;62:94–102.
26. C.J.Lee, Y.H.Lee, S.W.Park, K.J.Kim, S.Park, J.C.Youn,. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism. 2013;62:845–50.
27. S.G.Lakoski, F.Xu, G.L.Vega, S.M.Grundy, M.Chandalia, C.Lam,. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metabol. 2010;95:800–9.
28. M.Ghosh, C.Galman, M.Rudling, B.Angelin Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. J Lipid Res. 2015;56:463–9.
29. W.Guo, J.Fu, X.Chen, B.Gao, Z.Fu, H.Fan,. The effects of estrogen on serum level and hepatocyte expression of PCSK9. Metabolism. 2015;64:554–60.
30. E.P.Navarese, M.Kolodziejczak, V.Schulze, P.A.Gurbel, U.Tantry, Y.Lin,. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia:a systematic review and meta-analysis. Ann Intern Med. 2015;163:40–51.
31. J.C.Cohen, E.Boerwinkle, T.H.MosleyJr, H.H.Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.
32. Y.Nekaies, B.Baudin, S.Kelbousi, M.Sakly, N.Attia Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients. J Diabetes Complications. 2015;29:1165–70.